Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.

Malcolm Frier

Journal: Mini reviews in medicinal chemistry 2004;4(1):61-8

PMID: 14754444

Abstract

The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.

Address: Radiopharmacy Unit, Queens Medical Centre, Nottingham, UK. [email protected]

DOI: 10.2174/1389557043487510

Link outs

Free resources

Medical:

https://medlineplus.gov/bladdercancer.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

Subscription / membership required

Full Text Sources:

MeSH Terms: Biomarkers, Tumor, Copper Radioisotopes, Humans, Immunoconjugates, Isomerism, Mucin-1, Radioimmunodetection, Radioimmunotherapy, Radioisotopes, Radiopharmaceuticals, Rhenium, Urinary Bladder Neoplasms